Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$334.3 million.

  • Phathom Pharmaceuticals' Net Income towards Common Stockholders rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
  • As of FY2024, Phathom Pharmaceuticals' Net Income towards Common Stockholders stood at -$334.3 million, which was down 65.99% from -$201.4 million recorded in FY2023.
  • Phathom Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$129.2 million for FY2020, and its period low was -$334.3 million during FY2024.
  • For the 3-year period, Phathom Pharmaceuticals' Net Income towards Common Stockholders averaged around -$244.4 million, with its median value being -$201.4 million (2023).
  • Data for Phathom Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY crashed of 65.99% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Phathom Pharmaceuticals' Net Income towards Common Stockholders stood at -$129.2 million in 2020, then fell by 9.81% to -$141.8 million in 2021, then plummeted by 39.33% to -$197.6 million in 2022, then decreased by 1.92% to -$201.4 million in 2023, then plummeted by 65.99% to -$334.3 million in 2024.